Aetiopathogenesis and management of diabetic neuropathy

Journal of Association of Physicians of India

Volumn 50, Issue 5, 2002, Pages 707-711

  Afzaal, S ^a   Singh, M ^a   Saleem, I ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; REVIEW;

BLOOD GLUCOSE; DIABETIC NEUROPATHIES; HUMANS;

EID: 0036562324     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Marchai de Calvi. Recherches sur les accidents diabetiques. Paris. P Asserlin. 1864.
2. Peter D. Donofrio. Diabetic neuropathy. In : Leahy JL, Clark NG, Cefalu WT Ed., Medical management of diabetes mellitus. New York : Marcel Dekker, Inc. 2000;479-97.
3. Tesfaye S, Malik R, Ward JD. Vascular factors in diabetic neuropathy. Diabetologia 1994;37:847-54.
4. Tomlinson DR. The pharmacology of diabetic neuropathy. Diabetes Metab Rev 1992;7:67-84.
5. Melton LJ, Dyck PJ. Epidemiology. In Diabetic Neuropathy. Dyck PJ, Thomas PK, Winegrad AI, Porte D. Eds. Philadelphia. PA, Saunders. 1987;27-35.
6. Greene DA, Sima AAF, Albers JW, Pfeifer MA. Diabetic neuropathy. In Diabetes Mellitus. 4th ed. Rifkin H, Porte D, eds. New York, Elsevier. 1990;710-55.
7. Greene DA, Lattimer SA, Seemer AAF. Sorbitol, phosphoinositides and sodium - potassium ATPase in pathogenesis of diabetic complications. N Eng J Med 1987;316:599-606.
8. Tomlinson DR. Polyols and myoinositol in diabetic neuropathy - of mice and men. Mayo Clin Proc 1989;64:1030.
9. Horrobin DF. The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1988;31:181-97.
10. Pacifi L, Belluci A, Piovesan P, Maccari F, Gorio A, Ramacci MT. Counteraction on experimentally induced diabetic neuropathy by Plevocarnitine acetyl. Int J Clin Pharm Res 1992;12:231-6.
11. Gingliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.
12. Wohaib SA, Godin DV. Alterations in free radical tissue-defence mechanisms in streptozotocin-induced diabetes in rats. Effects of insulin treatment. Diabetes 1987;36:1;36:1;36:1;36:1014-8.
13. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxefield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow, and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994;37:449-59.
14. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994;10:189-224.
15. Cullum NA, Mahon J, Stringer K, et al. Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus. Diabetologia 1991;34:387.
16. Boulton AJM. New treatments for diabetic neuropathy. Curr Opin Endocrinol Diabetes 1996;3:330-4.
17. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Eng J Med 1993;329:977-86.
18. DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8.
19. Watkins PJ. Treatment for diabetic neuropathy. Diab Med 1996;13:1007-8.
20. Ziegler D. Diagnosis, staging and epidemiology of diabetic peripheral neuropathy. Diabetes Nutr Metab 1994;41:946-51.
21. Cameron NE, Cotter MA. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy : evidence from experimental studies. Diabet Med 1993;10:593-605.
22. Tomlinson DR. Aldose reductase inhibitors and the complications of diabetes. Diabet Med 1993;10:214-30.
23. Boulton AJM, Levin S, Comstock J. A multicentre trial of the aldose reductase inhibitor. Tolerastat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33:431-7.
24. Giugliano D, Marfella R, Quatrato A, et al. Tolerastat for mild diabetic neuropathy. A 52 week, randomized, placebo-controlled trial. Ann Intern Med 1993;118:7-11.
25. Didangelos TP, Karamitsos DT, Atheros VG, Kourtoglo GI. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of two years. J Diabetes and its Complications 1998;12:201-7.
26. Boulton AJM. Late sequelae of diabetic neuropathy. In Boulton AJM (ed.) : Diabetic Neuropathy. Lancaster. Marius Press. 1997;63-76.
27. Horrobin DF. Gamma-linoleic acid in the treatment of diabetic neuropathy. In Boulton AJM (ed.) : Diabetic Neuropathy. Lancaster. Marius Press. 1996;183-95.
28. Britland ST, Young RJ, Sharma AK, Clarke BF. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes 1990;39:909-13.
29. Tesfaye S, Harris N, Jakubowski J, et al. Impaired blood flow and arterio-venous shunting in human diabetic nephropathy. Diabetologia 1993;36:1266-74.
30. Stevens EJ, Lockett MJ, Carrington AL, Tomlinson DR. Essential fatty acid treatment prevents nerve ischaemia and associated conduction anomalies in rats with experimental diabetes mellitus. Diabetologia 1993;36:397-401.
31. Cameron NE, Cotter MA, Robertson S, Maxfield EK. Nerve function in experimental diabetes in rats : effects of electrical stimulation. Am J Physiol 1993;264:E161-6.
32. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Eng J Med 1988;318:1315-21.
33. Camera NE, Cotter MA, Dine K, Love A. Effects of aminoguanidine in peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992;35:946-50.
34. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessfer JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994;634:7-12.
35. Seckel BR. Enhancement of peripheral nerve regeneration. Muscle Nerve 1990;13:785-800.
36. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. NGF study group. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695-702.
37. Landi G, D'Allessandro R, Dosi BC, et al. Guillain Barre syndrome after exogeneous gangliosides in Italy. BMJ 1993;307:1463-4.
38. Baynes JW. Role of oxidative stress in the development of complications of diabetes. Diabetes 1991;40:405-12.
39. Low PA, Nickander KK. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991;40:873-7.
40. Woolf CJ. Recent advances in pathophysiology of acute pain. Br J Anaesth 1989;63:130-46.
41. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoraux L, Garofalo E for the Gabapentin Diabetic Neuropathy Study Group. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus : a randomized control trial. JAMA 1998;280:1831-6.
42. Vinik AI, Pittenger GL, McNitt P, Stansberry KB. Diabetic neuropathies : An overview of clinical aspects, pathogenesis and treatment. In : LeRoith D, Taylor SI and Olefsky JM, Eds., Diabetes Mellitus, 2nd ed. Philadelphia : Lippincott Williams and Wilkins. 2000;910-34.
43. Guy RJC, Dawson JL, Garret JR, et al. Diabetic gastroparesis in autonomic neuropathy : surgical considerations and changes in vagus nerve morphology. J Neurol Neurosurg Psychiatry 1984;47:686-91.
44. Campbell IW, Ewing DJ, Clarke BF. Therapeutic experience with fludrocortisone in diabetic postural hypotension. BMJ 1976;1:872-4.
45. Janka HV, Standl E, Menhert H. Clonidine effect on diabetic gustatory sweating. Ann Intern Med 1979;91:130.
46. Goldstein I, Lue TF, Padma-Nathan H Rosen RC, Steers WD, Wicker PA. Oral sidenfil in the treatment of erectile dysfunction. N Eng J Med 1998;338:1397-404.
47. Clayburgh RH, Beckenbaugh RD, Dobyns JH. Carpal tunnel release in patients with diffuse peripheral neuropathy. J Hand Surg 1987;12A:380-3.
48. Boulton AJM, Malik RA. Diabetic neuropathy. Med Clin North Am 1998;82:909-29.